8 ms·
This CEO is out for blood
- enimodas 12y agoI had to delete the header to be able to read the article. The constantly changing/flashing text just a couple of cm higher to where my eyes are focusing to read the article is very annoying.
- lilsunnybee 12y agoSame here. Thank God for being able to inspect and delete distracting page elements. I do feel sorry for readers not versed in html editing though.
- OrwellianChild 12y agoCan someone help me on the technical aspects of the blood tests they've developed? The premise appears to be that they take extremely small samples ("25 to 50 microliters") and run lots of tests ("as many as 70 different tests from a single draw") using "the same fundamental chemical methods". This compares with standard blood tests which require 2 orders of magnitude more blood ("numerous tubes of blood, each containing 3,000- to 5,000-microliter samples"). How does one produce reliable output with the same sensitivity/specificity using the same chemistry with so much less blood? I find it hard to believe that the existing lab procedures left that much efficiency on the table...
- jjoonathan 12y agoMicrofluidics. It's been a thing since the late 80s. http://www.rsc.org/ej/LC/2009/b911553f/b911553f-f1.gif http://www.rsc.org/ej/LC/2009/b911553f/b911553f-f1.gif Here's an early paper to use as a root for citation-chasing: http://www.sciencedirect.com/science/article/pii/092540059080209I http://www.sciencedirect.com/science/article/pii/09254005908... Here's a conference that has been going strong for 7 years: http://www.microtas2013.org/general.html http://www.microtas2013.org/general.html The technology has already been developed and proven in an academic setting. It's mature enough that you can find cheap textbooks for it. Microfluidic assays (which can be combined, like circuits, on a silicon chip) for every conceivable metric of interest have been developed, debugged, and sold to incumbent diagnostics companies. It was only a matter of time before someone integrated them, but the "usual suspects" were tripped up by market kinetics: No academic group has been sufficiently capitalized to pursue an "Integrate All The Assays" (IATA) project. A lab typically pursues 2 or 3 assays at a time, which they will often integrate into a "µTAS" which is academic slang for IATA but should get its own term because typical µTASs measure 2 or 3 things which is far below the potential of the technology (what I'm terming "IATA"). Industrial groups that were in a position to go IATA already had hard-won silos in the payola+bundling ridden rat's nest of the medical supply industry. They wanted to keep those (payola+bundling = low competition and high margins) and they didn't want to fight the war-on-many-fronts that would arise if they tried to invade everyone else's silos at once. The big risk is that their competitors in every silo could undercut/outmaneuver them in individual silos faster than they could weave a political network to unify purchasing across silos. Well, now someone has figured out how to do just that. Strategy: lots of money, lots of connections, and a killer entry strategy. It's all in the execution, as always. Two interesting questions to keep in mind as this plays out: 1. Now that someone has gone IATA, will the medical device supply industry become truly competitive again? I think there's a nonzero chance of that happening. That would be a dream come true for consumers and medtech startups alike. 2. How much of the proceeds will filter back to the people who actually developed the technology? Obviously the answer will be "a teeny tiny fraction," but the amount in absolute terms will be an important indicator (to me, personally, and I suspect others) as to how well the patent system works in this sector. Will it be like the software sector (patents discourage implementation AND don't encourage innovation) or will it be like the drug sector (patents function more or less as they were intended albeit with the caveat that a lion's share of the proceeds flows, as it always does, to capital)?
- peter-row 12y agoFTA, it seems she's front-running some approvals requirements and the sales / payola cycle by running a testing lab as well as developing the tests. To IT people, this is counterintuitive. You don't vertically integrate, you go for a horizontal slice. Intel won by making chips, not making whole systems (like IBM did). I guess vertical integration might make more sense in healthcare though, for regulatory and market reasons. I guess the market might be a bit more like IBM renting out mainframes than Intel selling CPU to OEMs. Also, making the tests cheaper (which is the main thing she's doing) might be unattractive to labs, if cost-plus pricing is popular - existing providers might not want to cut their prices.
- gone35 12y agoCan someone help me on the technical aspects of the blood tests they've developed? On the specifics, I'm afraid nobody can for now. They have refused to peer-review their protocols and validation data, so their assays are essentially a black box. So far, incredibly, they have managed to get away with this thanks to a glaring regulatory loophole (as the article explains); but sooner or later they'll have to open up if they want their assays to be taken seriously by the medical community. In broader terms, however, there's been a lot of recent work in the well-established microfluidics [1] literature on whole-blood assays [2], so that can give you a good guess about how they go about their implementation: most likely some form of "lab-on-a-disk" centrifugation for plasma separation and subsequent transport to separate microfluidic optical chambers preloaded with colorimetric reagents for readout, using perhaps a digital camera and some non-kosher/black-boxy form of curve-fitting DSP to increase "sensitivity". In all I'm very skeptical until they open up and provide peer-reviewed validation data for their assays. There are already several companies doing patented blood microfluidics like Abaxis [3] with peer-reviewed validation, and the enabling technologies have been out in the open in the literature for years, if not decades; so the whole "we are doing a super duper secret awesome thing we can't tell you anything about" sounds rather D-Wavey and fishy to me. [1] http://en.wikipedia.org/wiki/Microfluidics http://en.wikipedia.org/wiki/Microfluidics [2] http://mams.rmit.edu.au/vtkd17xbz90ez.pdf http://mams.rmit.edu.au/vtkd17xbz90ez.pdf [3] http://www.piccoloxpress.com http://www.piccoloxpress.com
- jjoonathan 12y agoIt's not fishy, it's just a business strategy rather than a tech strategy. They have a couple microfluidics assays that are profitable and they suspect these might be patent encumbered (even beyond the troll that they have already brought into the fold by giving him a board position.). Secrecy buys them two things: 1. Their competitors won't know what their loss leaders are. If assays A,B, and C have been optimized to profitability but D and E are still loss leaders, a competitor could use that knowledge by subsidizing demand for D and E (e.g. by undercutting them and forwarding the assay work, whereby the competitor spends $1 to force them to spend $10). 2. Patent trolls (are they really trolls if they spent money to develop the technology and make a product based on it?) won't know what to sue them for.
- 12y ago
- rurounijones 12y agoAnyone know a link to the patent in question at the beginning? some people have been decrying it as an "here is an idea" style with no substance, would help to have the thing available.
- pests 12y agoPosted elsewhere in the thread: https://www.google.com/patents/WO2005025413A3?cl=en&dq=ininventor:%22Elizabeth+A.+Holmes%22&hl=en&sa=X&ei=nu-sU8uqI46VyASChIDQAg&ved=0CBwQ6AEwAA https://www.google.com/patents/WO2005025413A3?cl=en&dq=ininv...
- deleted 12y ago[deleted]
- Htsthbjig 12y agoWow, the portrait of this woman is so photoshoped that is disgusting.
- anishkothari 12y agoThe link isn't working for me - Chrome on Windows. Edit: nevermind, Ghostery blocked everything except the navbar. In any case, I'm pulling for Theranos to be successful. I've had to have a lot of blood work done recently and I've been underwhelmed by every medical lab so far. If Theranos can use a smaller blood sample AND run more tests with it, then I can't wait to be a customer.
- kleiba 12y agoRobertson recounts. “And I kind of kicked myself. I’d consulted in this area for 30 years, but I’d never said, here we make all these gizmos that measure, and all these systems that deliver, but I never brought the two together.” Really? I hope this CEO chose the right partner... :-)
- rudimental 12y agoWow, what a story. They sound like they're killing it, the founder's motivation is admirable, and she's making a positive dent in the world. I hope they succeed. Inspiring.
- Procrastes 12y ago> “I realized that I could have just as well been looking into the eyes of a Steve Jobs or a Bill Gates.” > Though Theranos is largely unknown even in Silicon Valley, that is about to change. > Precisely how Theranos accomplishes all these amazing feats is a trade secret. > The analyzers look like large desktop computer towers. Holmes declines to explain how they work, or even allow them to be photographed, citing the need to protect trade secrets. The company manufactures them at an unmarked facility I toured in a research park across the South Bay from Palo Alto, in Newark, Calif. > the single most accomplished board in U.S. corporate history. It includes former U.S. Secretary of State, Treasury, and Labor George Shultz; former Secretary of Defense Bill Perry; former Secretary of State and National Security Adviser Henry Kissinger; and former U.S. Senators Sam Nunn and Bill Frist > In a rare if not unprecedented rout this past March, the patent holders unconditionally surrendered midtrial, stipulating to the invalidity of their own patent. As a kicker they agreed–though the presiding judge would have been powerless to order such a thing himself–to bring no additional patent suits against Theranos for five years. > retired U.S. Marine Corps Gen. James Mattis, explaining why he signed up last fall as another of Theranos’s strikingly illustrious outside directors. Mattis had stepped down just months earlier as commander of the U.S. Central Command–the chief of U.S. military operations in the Middle East and Central Asia ... zombie ... apocalypse
- JonnieCache 12y agoThe whole article was pretty weird. Anyone care to speculate what's going on here?
- ChuckMcM 12y agoPretty clear, they are getting significant traction in a market dominated by 'old school' companies and players. Perhaps their PR department wanted to get out front with the narrative :-). Having friends that work around the FDA's influence it is a very politicized space. She clearly built her board such that she could counter those threats.
- JonnieCache 12y ago
- dsr12 12y agoLoved this quote from her professor: “To me, I wish I wasn’t 70 years old. I wish I was her age and could be in on this. Because this is going to be a long, exciting, fascinating, exhilarating ride.”
- _mikz 12y agoWhat a crap fortune.com is. The article is nice though. edit: can't print it, does not work with ghostery/adblock, loads different articles after scrolling, ...
- namlem 12y agoIt works just fine with ABP
- illini123 12y agoAs a fellow health-tech entrepreneur, it's refreshing to see the business press reporting on something more than just "Yo." I hope this kind of publicity continues. The industry needs it.
- zhemao 12y agoSo what happened to the original idea? The patch that takes blood measurements while administering a drug? I can see how the current business is an extension of that original idea, but the article never states what became of the original. Did it die in the FDA approval process?
- dlss 12y agoSo no one has mentioned this yet, but this article is actually the Fortune cover story. And I think very much deserved, not for most of the details mentioned in the article, but because of their pricing page: http://www.theranos.com/test-menu http://www.theranos.com/test-menu -- it's freaking cheap.
- anishkothari 12y agoIt's almost absurdly cheap. If your health insurance doesn't cover your lab tests, then it's probably cheaper to travel to their testing centers in Arizona, get tested and go back home than go to a medical lab near you and pay out of pocket. On another note, I wonder why all except one of their testing centers are in and around Phoenix?
- ladytron 12y agoPhoenix is the Wild West. There is very little regulation or oversight, generally.
- tekacs 12y ago> she started her first business while still in high school, selling C++ compilers to Chinese universities. Along with the rest of the weirdness being mentioned by others, some of this really doesn't begin to make sense to me. o_O Custom compilers have been a thing a few times in the past, but in the late 90s, what possible reason could there be for this?
- Igglyboo 12y agoThe only thing I can think of was that the Chinese had some new architecture with no compiler out there for it. But if they had their own architecture they could surely build their own compiler.. Sounds fishy tbh
- w1ntermute 12y agoAnd I bet if you showed this article to someone with a background in the diagnostics industries Theranos is trying to disrupt, they would find all kinds of fishy aspects to those parts of the story as well.
- deleted 12y ago[deleted]
- dabit3 12y agoAwesome!
- balor123 12y agoWhat the company does sounds great. Maybe I skimmed through it too quickly but it starts out talking a lot about patches that measure the response to drugs. But then the company seems to just be doing blood tests quickly and cheaply. There was a pivot in there somewhere, right? Hard to tell with all the fluff around it. The article also mentions how they do it is trade secret but I'm curious what the innovations are here. They throw some things out there though, like bypassing FDA hurdles and shrinking equipment and blood sample size down. It sounds like they're just streamlining a sleepy, well entrenched industry? A noble endeavor but the juicy details would be nice if we could get them. Some day I hope that we can get these tests small and cheap enough that they could be purchased OTC and run easily and frequently at home. Collect a few hundred samples points while you check your weight in the morning and ship the data off to Amazon for data mining. It would wipe out surprise "I've had diabetes for the last 10 years and didn't realize it" diagnosis and that's a huge, huge win. Not to mention what the QS crowd would do with it. Not sure what to make of that bit about the restaurant. If she's really testing her blood after every meal, then I don't see how she could miss the impact her veggie, carb, low-protein, no-fat diet.
- DaniFong 12y agoWhy I'm excited about this, and you should be too: Tracking of biomarkers over time. "“The movie goal is absolutely core to what we’re working to do,”... We’re building an early-detection system,”
- deleted 12y ago[deleted]
- trhway 12y ago> Her father, Christian Holmes IV, has devoted most of his life to public-minded government service–disaster relief in Africa, international development projects in China, environmental work in this country–and is currently the global water coordinator for the U.S. Agency for International Development. He met Elizabeth’s mother, Noel, on Capitol Hill, where she worked as a congressional committee staffer. she definitely learnt a lot from her parents. At least how to navigate politically charged [mine]fields
- caycep 12y agoThere have been hints and whispers of Theranos here at HN for a while, here at least is more information about it, puff piece or no. The board is quite impressive; I suspect they have gotten at least some DoD money, i.e. DARPA, through which perhaps some of those connections were made...
- throwaway0626 12y agoThe CEO is definitely out for blood, and her employees apparently aren't exempt... Here's some more information about Theranos... I interviewed with these guys recently. One of the things the interviewer stressed is that the programmers there typically work 60-hour weeks, and would I be okay with that. He said he was very proud of the fact that they used to work 80-hour weeks but had gotten it down to about 60. I passed on them just for this one reason... The interview coding challenges were fairly well-designed and somewhat fun to do, though.
- throwaway3264 12y agoI was somewhat recently contacted for an interview, and the interviewer mentioned 45-55 hour work weeks, but other than that, the company seemed like it would be a decent company to work for. The screening process is somewhat more hardcore than others, but that can be a good thing.
- cmpns8 12y agoTheranos is nearing completion of a large new facility (corp hq?) in PA at the corner of Page Mill & Porter.
- jessaustin 12y agoHolmes had then just spent the summer working in a lab at the Genome Institute in Singapore, a post she had been able to fill thanks to having learned Mandarin in her spare hours as a Houston teenager. Everyone knows that English is spoken in Singapore, right? I'm not saying Mandarin wouldn't look good on a resume, but very few Singaporeans with the education to work in that facility would not also be fluent in the international language of science. Even if her work took place in community clinics, Mandarin wouldn't have been as helpful as e.g. Hokkien. EDIT: Since it's kind of lame that such a nitpick is still at the top, I'd like to address this also: Its advances relate to "optimizing the chemistry" and "leveraging software" to permit those conventional methods to work with tiny sample volumes. IANABiochemist, but they're talking about statistical methods here, right? My intuition is that a particular test performed at "nano"-scale might not be very accurate, but that a series of such tests could be as accurate as required.
- w1ntermute 12y agoI immediately picked up on that as well. Along with the whole "selling C++ compilers to Chinese universities in the late 90s" thing, it makes the article seem rather poorly researched and overly adulatory.
- deleted 12y ago[deleted]
- seanmcdirmid 12y agoHeck, I work in China and mandarin is hardly required.
- EdwardDiego 12y agoDo you blog about your experiences at all? If so, could I please have the url?
- seanmcdirmid 12y agoNo. I keep my laowai b*tching limited to foreigner bar nights. But if anyone ever wants to know something about living here, they can contact me by email.
- Gatsky 12y agoWell, cheaper and easier testing is great for everyone, particular in environments that can't run expensive fully equipped pathology laboratories eg rural areas, developing nations, refugee camps etc. But at the end of the day, we need better tests, not better ways of testing. Looking through their test menu, it's the same old diagnostic blood tests we've been using for the last 30 or even 50 years. Hopefully there is something revolutionary behind the hype. I don't think it will be consumerization - none of those listed tests is going to help early detection of anything by getting yourself tested at Walgreens while you're buying toothpaste. Similarly, most of the tests are only useful when applied in a well fleshed out diagnostic process that involves collecting data about symptoms and medical history to generate a prior probability of the disease. Otherwise the false positive rate is high, and the false negative rate difficult to deal with. The utility of serial monitoring as a marker of health is also far from proven, but is an interesting idea. At the moment though, if you go to your doctor and say your homocysteine levels are fluctuating strangely, they won't have a clue what to do about it... I would also add that proving that a test can be used to detect a disease early, and that early detection leads to a measurable improvement in disease outcomes takes a very long time, a lot of patients and a lot of money. So if they have made some great advance in microfluidic chemoproteomics that can actually detect the early traces of a disease process then that would be amazing, but one must remain skeptical.
- Geekette 12y agoImpressive to note that after raising $400 million, she still holds over 50% equity in the company.
- guiambros 12y agoWhat an amazing story. Best read of the entire week. It's 20 minutes well spent. A look at their website (and the profiles they're hiring for) gives a clear idea of where she is going. You don't need iOS/Android developers, or ASIC/FPGA designers, or hardware and mechanical engineers, to support Walgreen's Wellness centers. She's clearly going after the last mile. Blood tests for the masses. In your phone. No need for prescriptions, or visits to Walgreens. This is way bigger than a $90 billion dollars blood test industry.
- ejain 12y agoHere's another company going after the last mile, i.e. blood testing at home: https://cue.me/ https://cue.me/
- QuantumGood 12y agoAnd now we wait to see their connection with Apple's new health initiative...
- uireiu89 12y agothis is most trolling article and highly controversial data I have seen in years. For the fuck sake, she is playing with people's lives. She is 19 and claiming she knows all things and yet no one heard of her ? How is that possible ? All she is doing is using her father's contact. Just another get-super-rich-and-fuck-off scum scheme. If they are performing any kind of experiments without FDA approval it is unlawful. Fuck Fortune and all haters, radical feminists ( who is making gender issue out of discussion ) for ruining best university's name by using it as proxy.